TW202404661A - 用於治療癌症的組合療法 - Google Patents

用於治療癌症的組合療法 Download PDF

Info

Publication number
TW202404661A
TW202404661A TW112113000A TW112113000A TW202404661A TW 202404661 A TW202404661 A TW 202404661A TW 112113000 A TW112113000 A TW 112113000A TW 112113000 A TW112113000 A TW 112113000A TW 202404661 A TW202404661 A TW 202404661A
Authority
TW
Taiwan
Prior art keywords
azd5305
pharmaceutically acceptable
acceptable salt
enzalutamide
prostate cancer
Prior art date
Application number
TW112113000A
Other languages
English (en)
Chinese (zh)
Inventor
莎賓娜 琪亞拉 葛素利治
潔西卡 Ｓ 布朗
馬克 Ｒ 阿爾貝特拉
伊麗莎貝塔 里奧
Original Assignee
瑞典商阿斯特捷利康公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞典商阿斯特捷利康公司 filed Critical 瑞典商阿斯特捷利康公司
Publication of TW202404661A publication Critical patent/TW202404661A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112113000A 2022-04-07 2023-04-07 用於治療癌症的組合療法 TW202404661A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263362613P 2022-04-07 2022-04-07
US63/362,613 2022-04-07

Publications (1)

Publication Number Publication Date
TW202404661A true TW202404661A (zh) 2024-02-01

Family

ID=86226547

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112113000A TW202404661A (zh) 2022-04-07 2023-04-07 用於治療癌症的組合療法

Country Status (11)

Country Link
US (1) US20250213556A1 (https=)
EP (1) EP4504182A1 (https=)
JP (1) JP2025511402A (https=)
KR (1) KR20240170957A (https=)
CN (1) CN119212702A (https=)
AU (1) AU2023250031A1 (https=)
CA (1) CA3254949A1 (https=)
IL (1) IL316017A (https=)
MX (1) MX2024012392A (https=)
TW (1) TW202404661A (https=)
WO (1) WO2023194530A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202600137A (zh) * 2024-04-04 2026-01-01 美商輝瑞股份有限公司 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0705903B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Mutations in the 17q-linked breast and ovarian cancer susceptibility gene
DK0699754T3 (da) 1994-08-12 2001-02-26 Myriad Genetics Inc Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
MX2022000711A (es) 2019-07-19 2022-02-23 Astrazeneca Ab Inhibidores de parp1.

Also Published As

Publication number Publication date
JP2025511402A (ja) 2025-04-15
KR20240170957A (ko) 2024-12-05
CA3254949A1 (en) 2023-10-12
IL316017A (en) 2024-11-01
EP4504182A1 (en) 2025-02-12
CN119212702A (zh) 2024-12-27
WO2023194530A1 (en) 2023-10-12
US20250213556A1 (en) 2025-07-03
AU2023250031A1 (en) 2024-11-14
MX2024012392A (es) 2024-11-08

Similar Documents

Publication Publication Date Title
JP2003523944A (ja) Ｐ−糖タンパク質修飾物質を用いる抗ウィルス療法
TW202404661A (zh) 用於治療癌症的組合療法
TW202404593A (zh) 用於治療癌症的組合療法
CN115038447A (zh) 用于治疗癌症的组合疗法
US20250228847A1 (en) Combination therapy for treating cancer
KR20260010420A (ko) 암 치료를 위한 parp1 억제제 및 선택적 에스트로겐 분해제의 병용
WO2024088192A1 (en) An aurora a inhibitor for use in treatments of cancers
US20250170146A1 (en) Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
KR20240056487A (ko) 고형 종양을 치료하기 위한 약제학적 조성물
KR20250023494A (ko) 암 치료를 위한 병용 요법
US20060009475A1 (en) Quinazolinone compounds in combined modalities for improved cancer treatment
HK1175719A (en) Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea